Company

We are building a new factory and broke ground on October 26^th, 2023.

Built on a 7,000 sqm (70,000 sqft) greenfield development lot, the new Spineart factory is our third production site and our largest so far with more than 4,200 sqm (42,000 sqft) and will eventually regroup all our manufacturing and logistics activities. It will be equipped with state-of-the-art additive manufacturing, CNC machines and a new clean room. This new site will support Spineart continued double-digit growth through a significant manufacturing footprint expansion and the integration of the latest manufacturing innovations as well as sustainability standards.

The new factory is located close to our global headquarters in Geneva, Switzerland, in a region renowned for being a center of excellence for precision manufacturing.

The official opening of the new Spineart factory is scheduled early 2025.

For the first time in its history, Spineart has reached and surpassed €100m of trailing 12-month revenue.

As the success and expansion of the Ti-LIFE ranges continues, we are rolling out the posterior fixation PERLA® platform and actively invest and develop multiple enabling technologies for spine surgeries, as exemplified by its co-development agreement with eCential robotics.

We are steadily gaining market share in Europe where the MDR certification of our full portfolio is well ahead of our peers and in the US through the addition of state-of-the-art systems to our portfolio. Our 2 US IDE trials for the BAGUERA® C cervical disc prothesis are enrolling at full speed and we are aiming for enrollment completion in the coming months. Meanwhile the 10-year safety and efficacy data for BAGUERA® C collected from Europe have been published in the prestigious European Spine Journal.

Spineart is committed to transform spine surgery for patients, surgeons and hospitals as we aim to create safe solutions and ultimately advance healthcare worldwide.